Good example to use for evaluating the power analysis
| View/Edit | Study Name | Start Date | Study Types | Experimental Models | Model Types | Disease(s) | Data Points | Data Points (omic) | Images | Videos | Plate Maps | Plate Reader Files | Supporting Data Files | Description | Reproducibility Status | Center | Data Entry | Review | Sign Off Date | Data Provider | ID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| View/Edit | UPLiver_Tier2c_3D | 2018-08-31 | TOX | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 2,150 | 0 | 54 | 0 | 0 | 0 | 2 | This tier of testing was part of the 3D “Toxicity” study to measure the effects of drugs on cells seeded in SQL-SAL tissue chips. In this study, 27 chips (Nortis, Inc.) were seeded with iPSC-derived hepatocytes from CDI, as well as supporting cells (LX-2, EA.Hy926, and THP-1) in a layered collagen matrix. Cultures were treated with either a vehicle (0.1% DMSO, n=3), caffeine (600uM, n=3), trovafloxacin (150uM, n=3), troglitazone (28uM, n=3), tolcapone (88uM, n=3), rosiglitazone (0.8uM, n=3), pioglitazone (3uM, n=3), trovaflocacin + LPS (150uM + 1ug/mL, n=3), or LPS (1ug/mL, n=3). Cells were cultured over 10 days with daily media sampling. Media was tested for flow rate, Albumin, Urea-Nitrogen, LDH, and TNF-a, as well as the presence of the parent drug compounds. Additionally, viability testing was carried out at endpoint. | TEX-VAL | Michael Castiglione | 4 | 2019-07-11 | Rusyn_TAMU | 225 |